title: An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer.
abstract: The growing incidence rate of breast cancer, coupled with cellular chemotherapeutic resistance, has made this disease one of the most prevalent cancers among women worldwide. Despite the recent efforts to understand the underlying cause of the resistance due to mutation, there are no feasible tactics to overcome this bottleneck. This issue could be addressed by the concept of polypharmacology-disguising drugs present in the pharmacopeia for novel purposes (drug repurposing). Of note, we have proposed a multi-modal computational drug-repositioning stratagem to predict drugs possessing anti-proliferative effect. Our results suggest that Ombitasvir, a Hepatitis C NS5B polymerase inhibitor, could be "repurposed" for the control and prevention of beta-tubulin-driven breast cancers. J. Cell. Biochem. 118: 1412-1422, 2017. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Biotechnology, School of Bio Sciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
authors.forename: Ramanathan
authors.initials: R
authors.lastname: Karuppasamy
authors.affiliation: Department of Biotechnology, School of Bio Sciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
authors.forename: Kanika
authors.initials: K
authors.lastname: Verma
authors.affiliation: Department of Biotechnology, School of Bio Sciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
authors.forename: Velin Marita
authors.initials: VM
authors.lastname: Sequeira
authors.affiliation: Department of Biotechnology, School of Bio Sciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
authors.forename: Lokapriya Nandan
authors.initials: LN
authors.lastname: Basavanna
authors.affiliation: Department of Biotechnology, School of Bio Sciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
authors.forename: Shanthi
authors.initials: S
authors.lastname: Veerappapillai
mesh_terms: D000813:Anilides / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D002219:Carbamates / Q000494:pharmacology* / Q000627:therapeutic use; D019295:Computational Biology / Q000379:methods; D058492:Drug Repositioning / Q000379:methods*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008958:Models, Molecular; D062105:Molecular Docking Simulation; D009154:Mutation; D017239:Paclitaxel; D064798:Polypharmacology; D011392:Proline; D014404:Tubulin / Q000235:genetics*; D014633:Valine
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D002219:Carbamates; D014404:Tubulin; C586094:ombitasvir; D011392:Proline; D014633:Valine; D017239:Paclitaxel
keywords: ANTI-VIRAL DRUGS; BREAST CANCER; DRUG-REPURPOSING; PACLITAXEL